Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. (Q37975254)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 October 2011

Language	Label	Description	Also known as
English	Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.	scientific article published on 30 October 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Seyed Moayed Alavian

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

S V Tabatabaei

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

B Behnava

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

30 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

88-93

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Development and validation of MIX: comprehensive free software for meta-analysis of causal research data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37975254&oldid=2097575068"